Amgen Inc.
AMGNHealthcareNASDAQDrug Manufacturers - General · Last scanned May 30, 2026
Scan Results
Daily timeframeAmgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. At a $181.77B market cap, Amgen Inc. ranks as a large-cap company within healthcare. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEP.
Market Cap
$181.77B
Beta
0.43
P/E (TTM)
23.44
P/E (Fwd)
14.35
EPS (TTM)
$14.37
EPS (Fwd)
$23.48
ROE
101.3%
ROA
8.3%
Cash
$12.04B
Total Debt
$57.32B
Free CF
$7.44B
52W Change
16.8%
Annual Financials
Cash vs Debt
Amgen Inc. carries $57.32B in total debt against $12.04B in cash reserves — debt is roughly 4.8x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $7.44B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 101.3%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 8.3% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $26.32B (2022) to $36.75B (2025), reflecting a 40% increase over the period.
With a beta below 0.7, Amgen Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Amgen Inc.'s trajectory.